内容紹介
Summary
Aim: This study aimed to retrospectively evaluate the efficacy and safety of capecitabine plus oxaliplatin(CapeOX)for heavily pretreated advanced gastric cancer(AGC)refractory to S-1, cisplatin, irinotecan, and taxanes. Methods: Twelve patients with AGC refractory to S-1, cisplatin, irinotecan, and taxanes were enrolled in this study. Treatment comprised capecitabine(1,000 mg/m2 twice a day on days 1-14)and oxaliplatin(130 mg/m2 on day 1). Cycles were repeated at 3-week intervals. Results: The overall response rate was 16.7%, and the disease control rate at 6 weeks was 75.0%. The progression free survival was 3.1 months, and the overall survival was 8.3 months after initiation of CapeOX therapy. The most common hematological toxicity was grade 3 neutropenia(50%). Peripheral neuropathy of Grade 1 or 2 was found in 50% of cases, but no Grade 3 or 4 neuropathy was found. Conclusions: CapeOX showed some activities as salvage therapy for heavily pretreated AGC patients. We suggest that CapeOX therapy should be considered a treatment option for pretreated AGC with good performance status.
要旨
目的: S-1,シスプラチン,イリノテカン,タキサン製剤に耐性となった進行胃癌症例におけるCapeOX療法の有効性と安全性を検討する。方法: 対象はS-1,シスプラチン,イリノテカン,タキサン製剤に耐性となりCapeOXを施行した12例の進行胃癌症例とし,その有効性と安全性について後方視的に解析した。結果: 奏効率16.7%,病勢コントロール率は75.0%であった。無増悪生存期間の中央値3.1か月,CapeOX開始後の全生存期間の中央値は8.3か月であった。有害事象はGrade 3の好中球減少,Grade 1～2の末梢神経障害を半数の症例で認めた。結論: CapeOX療法は既治療の進行胃癌症例に一定の効果がみられ,また有害事象も忍容可能なものであり,救済治療の選択肢の一つになり得ることが示唆された。
目次
Aim: This study aimed to retrospectively evaluate the efficacy and safety of capecitabine plus oxaliplatin(CapeOX)for heavily pretreated advanced gastric cancer(AGC)refractory to S-1, cisplatin, irinotecan, and taxanes. Methods: Twelve patients with AGC refractory to S-1, cisplatin, irinotecan, and taxanes were enrolled in this study. Treatment comprised capecitabine(1,000 mg/m2 twice a day on days 1-14)and oxaliplatin(130 mg/m2 on day 1). Cycles were repeated at 3-week intervals. Results: The overall response rate was 16.7%, and the disease control rate at 6 weeks was 75.0%. The progression free survival was 3.1 months, and the overall survival was 8.3 months after initiation of CapeOX therapy. The most common hematological toxicity was grade 3 neutropenia(50%). Peripheral neuropathy of Grade 1 or 2 was found in 50% of cases, but no Grade 3 or 4 neuropathy was found. Conclusions: CapeOX showed some activities as salvage therapy for heavily pretreated AGC patients. We suggest that CapeOX therapy should be considered a treatment option for pretreated AGC with good performance status.
要旨
目的: S-1,シスプラチン,イリノテカン,タキサン製剤に耐性となった進行胃癌症例におけるCapeOX療法の有効性と安全性を検討する。方法: 対象はS-1,シスプラチン,イリノテカン,タキサン製剤に耐性となりCapeOXを施行した12例の進行胃癌症例とし,その有効性と安全性について後方視的に解析した。結果: 奏効率16.7%,病勢コントロール率は75.0%であった。無増悪生存期間の中央値3.1か月,CapeOX開始後の全生存期間の中央値は8.3か月であった。有害事象はGrade 3の好中球減少,Grade 1～2の末梢神経障害を半数の症例で認めた。結論: CapeOX療法は既治療の進行胃癌症例に一定の効果がみられ,また有害事象も忍容可能なものであり,救済治療の選択肢の一つになり得ることが示唆された。